Benzocaine

Product Overview

Benzocaine was first synthesized in 1890 by German chemist Eduard Ritsert, who was searching for a less toxic and non-addictive alternative to cocaine, which at the time was the only effective local anesthetic. Ritsert's key insight was that the ethyl ester of p-aminobenzoic acid (PABA) retained the anesthetic activity of cocaine's benzoyl ester moiety while eliminating its central nervous system stimulant effects. He introduced it commercially as Anästhesin in 1902, and it quickly became the preferred oral/topical anesthetic for dental procedures and minor surgery. Benzocaine was the first fully synthetic local anesthetic — all later compounds in both the ester and amide classes trace their development lineage to this discovery.

Benzocaine works by reversibly binding to and blocking voltage-gated sodium channels in neuronal cell membranes, preventing the sodium influx required for action potential generation and propagation. Because benzocaine is almost completely insoluble in water (approximately 0.4 g/L), it is exclusively used for topical/surface anesthesia — it cannot be injected as a solution. This insolubility is actually its key clinical advantage: benzocaine stays exactly where it is applied, providing localized anesthesia at mucosal and skin surfaces with negligible systemic absorption and minimal risk of systemic toxicity. This property makes it the safest local anesthetic for loose, non-sterile topical applications where systemic effects would be undesirable.

Benzocaine belongs to the ester class of local anesthetics, which are metabolized by plasma pseudocholinesterases (butyrylcholinesterase) rather than by hepatic CYP450 enzymes like the amide class (lidocaine, bupivacaine). This plasma-based metabolism means benzocaine has a very short plasma half-life of approximately 30-60 seconds if any is absorbed systemically. The primary degradation product is p-aminobenzoic acid (PABA), which is renally excreted. Compared to other ester anesthetics like procaine, benzocaine has much lower allergenicity — a property that has made it the preferred ester anesthetic for OTC products for over a century.

Benzocaine is one of the most widely used pharmaceutical API molecules in consumer healthcare products globally. It is the active ingredient in OTC teething gels, sore throat lozenges and sprays, hemorrhoid creams, sunburn analgesics, dental anesthetic gels (typically 20%), oral ulcer treatments, and otic preparations for ear pain. The global benzocaine API market is substantial, estimated in the hundreds of millions of USD, with China as the dominant production hub. KingWish supplies GMP-certified benzocaine meeting USP, EP, and BP standards.

Quality Specifications

Applications

• Topical anesthetic creams and gels: OTC topical anesthetic for minor skin irritations, insect bites, sunburn, and hemorrhoids at concentrations of 5-20%.
• Dental anesthesia: 20% benzocaine gel for pre-injection topical mucosal anesthesia in dental procedures. Rapid onset oral mucosal numbing.
• Sore throat lozenges: Benzocaine-containing lozenges and sprays for temporary relief of sore throat and mouth pain. Typical concentration: 5-15 mg per lozenge.
• Minor wound and burn pain relief: Topical spray, cream, and ointment formulations for first-degree burns, sunburn, minor cuts, and abrasions.
• Otic preparations for ear pain: Benzocaine-containing ear drops for temporary relief of otalgia. Often combined with antipyrine in prescription and OTC formulations.